Form 4: Inari Medical CEO Andrew Hykes Sells Shares Under 10b5-1 Trading Plan

Inari Medical's CEO, Andrew Hykes, sold 3,000 shares of common stock at $50 per share on May 28, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Andrew Hykes, the President and CEO of Inari Medical, Inc., reported a transaction involving the sale of 3,000 shares of common stock on May 28, 2024.
• The sale was executed at a price of $50 per share.
• Following the transaction, Hykes directly owns 465,474 shares of Inari Medical common stock.
• He also indirectly owns 1,550 shares through each of his three children and 1,000 shares through his spouse.
• The transaction was conducted under a Rule 10b5-1 trading plan adopted on November 13, 2023.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The transaction is a routine sale under a pre-arranged trading plan and doesn't necessarily indicate a negative outlook on the company.

Positives

• The sale was conducted under a pre-arranged 10b5-1 trading plan, which is often viewed as a way for insiders to sell shares without raising concerns about insider trading, as the plan is established in advance.

Risks

• While the sale was under a 10b5-1 plan, large insider sales can sometimes be perceived negatively by investors, potentially creating short-term downward pressure on the stock price.

Industry Context

Insider transactions are routinely monitored and reported, providing transparency to investors. Sales by executives are not inherently negative, especially when conducted under pre-arranged trading plans. It's common for executives to diversify their holdings for personal financial management.

Comparison to Industry Standards

• Comparing Inari Medical's insider trading activity to companies like Penumbra, Inc. (PEN) or Boston Scientific Corporation (BSX) shows that regular insider transactions are a normal part of executive compensation and portfolio management.
• The use of 10b5-1 plans is a common practice among executives in publicly traded companies to avoid accusations of trading on non-public information, similar to practices seen at Edwards Lifesciences (EW).

Stakeholder Impact

• The sale could have a minor short-term impact on shareholders if it creates downward pressure on the stock price, but the use of a 10b5-1 plan mitigates concerns about insider trading.

Key Dates